Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Edwin A M Gale

Showing results (1-10 of 54) with videos related to

Pageof 6
Sort By:
Diabetes Care|November 23, 2013
Response to comment on: Butler et al. A critical analysis of the clinical use of incretin-based therapies: are the GLP-1 therapies safe? Diabetes Care 2013;36:2118-2125Edwin A M Gale
Diabetes|April 21, 2012
GLP-1-based therapies and the exocrine pancreas: more light, or just more heat?Edwin A M Gale
Clinical Medicine (London, England)|January 2, 2004
Between two cultures: the expert clinician and the pharmaceutical industryEdwin A M Gale
Diabetes|November 28, 2002
The rise of childhood type 1 diabetes in the 20th centuryEdwin A M Gale
The New England Journal of Medicine|May 31, 2002
Can we change the course of beta-cell destruction in type 1 diabetes?Edwin A M Gale
BMJ (Clinical Research Ed.)|March 22, 2008
Should we dump the metabolic syndrome? YesEdwin A M Gale
Diabetologia|July 19, 2005
The myth of the metabolic syndromeEdwin A M Gale
BMJ (Clinical Research Ed.)|September 13, 2012
Newer insulins in type 2 diabetesEdwin A M Gale
Nature Reviews. Endocrinology|November 25, 2010
Therapy: The second time as farce: rosiglitazone and the regulatorsEdwin A M Gale
Diabetologia|December 25, 2004
Your journal and mineEdwin A M Gale
Pageof 6

Showing results (1-10 of 54) with videos related to

Sort By:
Pageof 6
Diabetes Care|November 23, 2013
Response to comment on: Butler et al. A critical analysis of the clinical use of incretin-based therapies: are the GLP-1 therapies safe? Diabetes Care 2013;36:2118-2125Edwin A M Gale
Diabetes|April 21, 2012
GLP-1-based therapies and the exocrine pancreas: more light, or just more heat?Edwin A M Gale
Clinical Medicine (London, England)|January 2, 2004
Between two cultures: the expert clinician and the pharmaceutical industryEdwin A M Gale
Diabetes|November 28, 2002
The rise of childhood type 1 diabetes in the 20th centuryEdwin A M Gale
The New England Journal of Medicine|May 31, 2002
Can we change the course of beta-cell destruction in type 1 diabetes?Edwin A M Gale
BMJ (Clinical Research Ed.)|March 22, 2008
Should we dump the metabolic syndrome? YesEdwin A M Gale
Diabetologia|July 19, 2005
The myth of the metabolic syndromeEdwin A M Gale
BMJ (Clinical Research Ed.)|September 13, 2012
Newer insulins in type 2 diabetesEdwin A M Gale
Nature Reviews. Endocrinology|November 25, 2010
Therapy: The second time as farce: rosiglitazone and the regulatorsEdwin A M Gale
Diabetologia|December 25, 2004
Your journal and mineEdwin A M Gale
Pageof 6